vs
ABVC BIOPHARMA, INC.（ABVC）与安进（AMGN）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是ABVC BIOPHARMA, INC.的12395.3倍（$9.9B vs $796.0K）。安进净利率更高（13.5% vs -256.6%，领先270.1%）。ABVC BIOPHARMA, INC.同比增速更快（104.5% vs 8.6%）。过去两年ABVC BIOPHARMA, INC.的营收复合增速更高（1041.5% vs 15.1%）
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
ABVC vs AMGN — 直观对比
营收规模更大
AMGN
是对方的12395.3倍
$796.0K
营收增速更快
ABVC
高出95.9%
8.6%
净利率更高
AMGN
高出270.1%
-256.6%
两年增速更快
ABVC
近两年复合增速
15.1%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $796.0K | $9.9B |
| 净利润 | $-2.0M | $1.3B |
| 毛利率 | 100.0% | 69.8% |
| 营业利润率 | -246.8% | 27.6% |
| 净利率 | -256.6% | 13.5% |
| 营收同比 | 104.5% | 8.6% |
| 净利润同比 | -417.4% | 112.6% |
| 每股收益（稀释后） | $-0.09 | $2.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABVCAMGN
| Q4 25 | — | $9.9B | ||
| Q3 25 | $796.0K | $9.6B | ||
| Q2 25 | — | $9.2B | ||
| Q1 25 | — | $8.1B | ||
| Q4 24 | $2.0K | $9.1B | ||
| Q3 24 | $389.3K | $8.5B | ||
| Q2 24 | $117.1K | $8.4B | ||
| Q1 24 | $1.2K | $7.4B |
净利润ABVCAMGN
| Q4 25 | — | $1.3B | ||
| Q3 25 | $-2.0M | $3.2B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | $-731.6K | $627.0M | ||
| Q3 24 | $-394.8K | $2.8B | ||
| Q2 24 | $-942.3K | $746.0M | ||
| Q1 24 | $-2.8M | $-113.0M |
毛利率ABVCAMGN
| Q4 25 | — | 69.8% | ||
| Q3 25 | 100.0% | 67.8% | ||
| Q2 25 | — | 67.2% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | 100.0% | 65.7% | ||
| Q3 24 | 99.9% | 61.1% | ||
| Q2 24 | 99.8% | 61.4% | ||
| Q1 24 | 77.0% | 57.0% |
营业利润率ABVCAMGN
| Q4 25 | — | 27.6% | ||
| Q3 25 | -246.8% | 26.4% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 14.5% | ||
| Q4 24 | -35837.4% | 25.4% | ||
| Q3 24 | -77.7% | 24.1% | ||
| Q2 24 | -734.2% | 22.8% | ||
| Q1 24 | -235539.8% | 13.3% |
净利率ABVCAMGN
| Q4 25 | — | 13.5% | ||
| Q3 25 | -256.6% | 33.7% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 21.2% | ||
| Q4 24 | -37211.3% | 6.9% | ||
| Q3 24 | -101.4% | 33.3% | ||
| Q2 24 | -804.4% | 8.9% | ||
| Q1 24 | -235203.2% | -1.5% |
每股收益（稀释后）ABVCAMGN
| Q4 25 | — | $2.45 | ||
| Q3 25 | $-0.09 | $5.93 | ||
| Q2 25 | — | $2.65 | ||
| Q1 25 | — | $3.20 | ||
| Q4 24 | $-0.02 | $1.17 | ||
| Q3 24 | $-0.03 | $5.22 | ||
| Q2 24 | $-0.08 | $1.38 | ||
| Q1 24 | $-0.29 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.2K | $9.1B |
| 总债务越低越好 | — | $54.6B |
| 股东权益账面价值 | $12.1M | $8.7B |
| 总资产 | $21.2M | $90.6B |
| 负债/权益比越低杠杆越低 | — | 6.31× |
8季度趋势，按日历期对齐
现金及短期投资ABVCAMGN
| Q4 25 | — | $9.1B | ||
| Q3 25 | $257.2K | $9.4B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $8.8B | ||
| Q4 24 | $313.1K | $12.0B | ||
| Q3 24 | $208.2K | $9.0B | ||
| Q2 24 | $200.0K | $9.3B | ||
| Q1 24 | $106.4K | $9.7B |
总债务ABVCAMGN
| Q4 25 | — | $54.6B | ||
| Q3 25 | — | $54.6B | ||
| Q2 25 | — | $56.2B | ||
| Q1 25 | — | $57.4B | ||
| Q4 24 | — | $60.1B | ||
| Q3 24 | — | $60.4B | ||
| Q2 24 | — | $62.6B | ||
| Q1 24 | — | $64.0B |
股东权益ABVCAMGN
| Q4 25 | — | $8.7B | ||
| Q3 25 | $12.1M | $9.6B | ||
| Q2 25 | — | $7.4B | ||
| Q1 25 | — | $6.2B | ||
| Q4 24 | $1.2M | $5.9B | ||
| Q3 24 | $1.6M | $7.5B | ||
| Q2 24 | $1.8M | $5.9B | ||
| Q1 24 | $1.7M | $5.0B |
总资产ABVCAMGN
| Q4 25 | — | $90.6B | ||
| Q3 25 | $21.2M | $90.1B | ||
| Q2 25 | — | $87.9B | ||
| Q1 25 | — | $89.4B | ||
| Q4 24 | $7.5M | $91.8B | ||
| Q3 24 | $7.8M | $90.9B | ||
| Q2 24 | $8.0M | $90.9B | ||
| Q1 24 | $8.0M | $93.0B |
负债/权益比ABVCAMGN
| Q4 25 | — | 6.31× | ||
| Q3 25 | — | 5.67× | ||
| Q2 25 | — | 7.57× | ||
| Q1 25 | — | 9.24× | ||
| Q4 24 | — | 10.23× | ||
| Q3 24 | — | 8.02× | ||
| Q2 24 | — | 10.57× | ||
| Q1 24 | — | 12.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-964.7K | $1.6B |
| 自由现金流经营现金流 - 资本支出 | — | $961.0M |
| 自由现金流率自由现金流/营收 | — | 9.7% |
| 资本支出强度资本支出/营收 | — | 6.5% |
| 现金转化率经营现金流/净利润 | — | 1.20× |
| 过去12个月自由现金流最近4个季度 | — | $8.1B |
8季度趋势，按日历期对齐
经营现金流ABVCAMGN
| Q4 25 | — | $1.6B | ||
| Q3 25 | $-964.7K | $4.7B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $-702.1K | $4.8B | ||
| Q3 24 | $60.2K | $3.6B | ||
| Q2 24 | $-211.4K | $2.5B | ||
| Q1 24 | $-955.8K | $689.0M |
自由现金流ABVCAMGN
| Q4 25 | — | $961.0M | ||
| Q3 25 | — | $4.2B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $980.0M | ||
| Q4 24 | — | $4.4B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $459.0M |
自由现金流率ABVCAMGN
| Q4 25 | — | 9.7% | ||
| Q3 25 | — | 44.4% | ||
| Q2 25 | — | 20.8% | ||
| Q1 25 | — | 12.0% | ||
| Q4 24 | — | 48.4% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 26.5% | ||
| Q1 24 | — | 6.2% |
资本支出强度ABVCAMGN
| Q4 25 | — | 6.5% | ||
| Q3 25 | — | 4.6% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | — | 3.0% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 3.1% |
现金转化率ABVCAMGN
| Q4 25 | — | 1.20× | ||
| Q3 25 | — | 1.46× | ||
| Q2 25 | — | 1.59× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 7.61× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 3.30× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABVC
暂无分部数据
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
